

# Paolo Sciattella

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6397914/publications.pdf>

Version: 2024-02-01

27  
papers

480  
citations

759055

12  
h-index

713332

21  
g-index

30  
all docs

30  
docs citations

30  
times ranked

1051  
citing authors

#	ARTICLE	IF	CITATIONS
1	The sexist behaviour of immune checkpoint inhibitors in cancer therapy?. <i>Oncotarget</i> , 2017, 8, 99336-99346.	0.8	76
2	Cost of poor adherence to anti-hypertensive therapy in five European countries. <i>European Journal of Health Economics</i> , 2015, 16, 65-72.	1.4	66
3	PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?. <i>BioMed Research International</i> , 2017, 2017, 1-7.	0.9	49
4	Cost of chronic and episodic migraine patients in continuous treatment for two years in a tertiary level headache Centre. <i>Journal of Headache and Pain</i> , 2019, 20, 120.	2.5	46
5	Economic aspects in the management of diabetes in Italy. <i>BMJ Open Diabetes Research and Care</i> , 2016, 4, e000197.	1.2	22
6	Economic burden of diverticular disease: An observational analysis based on real world data from an Italian region. <i>Digestive and Liver Disease</i> , 2017, 49, 1003-1008.	0.4	22
7	Rapid referral for headache management from emergency department to headache centre: four years data. <i>Journal of Headache and Pain</i> , 2020, 21, 25.	2.5	22
8	Direct and indirect costs of cluster headache: a prospective analysis in a tertiary level headache centre. <i>Journal of Headache and Pain</i> , 2020, 21, 44.	2.5	16
9	The Impact of COVID-19 Vaccination on the Italian Healthcare System: A Scenario Analysis. <i>Clinical Drug Investigation</i> , 2022, 42, 237-242.	1.1	16
10	Economic evaluation of spondyloarthritis: economic impact of diagnostic delay in Italy. <i>ClinicoEconomics and Outcomes Research</i> , 2018, Volume 10, 45-51.	0.7	15
11	Budget Impact Analysis of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections in Three European Countries. <i>Clinical Drug Investigation</i> , 2020, 40, 305-318.	1.1	15
12	The Tradeoff between Travel Time from Home to Hospital and Door to Balloon Time in Determining Mortality among STEMI Patients Undergoing PCI. <i>PLoS ONE</i> , 2016, 11, e0158336.	1.1	15
13	Socioeconomic differences in one-year survival after ischemic stroke: the effect of acute and post-acute care-pathways in a cohort study. <i>BMC Public Health</i> , 2016, 16, 408.	1.2	13
14	Economic evaluation of the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) from the national payer perspective: introduction of a new treatment to the patient journey. A simulation of three European countries. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 581-599.	0.7	12
15	Treatment plan comparison in acute and chronic respiratory tract diseases: an observational study of doxophylline vs. theophylline. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 503-510.	0.7	11
16	Osteoporosis: Economic Burden of Disease in Italy. <i>Clinical Drug Investigation</i> , 2020, 40, 449-458.	1.1	10
17	The Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need Trial. <i>Vaccines</i> , 2020, 8, 191.	2.1	10
18	The burden of atopic dermatitis in adults in Italy. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 19-23.	0.8	8

#	ARTICLE	IF	CITATIONS
19	Economic burden of HPV9-related diseases: a real-world cost analysis from Italy. <i>European Journal of Health Economics</i> , 2019, 20, 829-840.	1.4	7
20	High quality process of care increases one-year survival after acute myocardial infarction (AMI): A cohort study in Italy. <i>PLoS ONE</i> , 2019, 14, e0212398.	1.1	7
21	An Analysis of the Social and Economic Costs of Breast Cancer in Italy. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 9005.	1.2	7
22	Burden of Disease of Human Papillomavirus (HPV): Hospitalizations in the Marche and Veneto Regions. An observational study. <i>Clinical Drug Investigation</i> , 2018, 38, 173-180.	1.1	6
23	Healthcare Resource Utilization, Cardiovascular Event Rate and Use of Lipid-Lowering Therapies in Secondary Prevention of ASCVD in Hospitalized Patients in Italy. <i>Advances in Therapy</i> , 2022, 39, 314-327.	1.3	5
24	Economic Impact of Schizophrenia from a Hospital and Social Security System Perspective in Italy. <i>Clinical Drug Investigation</i> , 2021, 41, 183-191.	1.1	4
25	PP092 Real World Data: Biologic Treatment For Naive Patients In Lazio Region. <i>International Journal of Technology Assessment in Health Care</i> , 2017, 33, 114-115.	0.2	0
26	PP130 Economic Burden Of Nine Human Papillomavirus Strains (HPV9)-Related Diseases: A Real World Cost Analysis From Italy. <i>International Journal of Technology Assessment in Health Care</i> , 2018, 34, 117-118.	0.2	0
27	The impact of locoregional treatment on response to nivolumab in advanced platinum refractory head and neck cancer: The need trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, e18508-e18508.	0.8	0